Emerson Electric Co. (EMR): Director Arthur F. Golden Bought 2,000 Shares
Director of Emerson Electric Co., Arthur F. Golden, bought 2,000 shares on June 6, 2011, at an average price of $52.06. Emerson is engaged principally in the worldwide design, manufacture and sale of a broad range of electrical, electromechanical and electronic products and systems. Emerson Electric Co. has a market cap of $39.13 billion; its shares were traded at around $52.06 with a P/E ratio of 17.7 and P/S ratio of 1.9. The dividend yield of Emerson Electric Co. stocks is 2.6%. Emerson Electric Co. had an annual average earnings growth of 9.6% over the past 10 years. GuruFocus rated Emerson Electric Co. the business predictability rank of 2.5-star.
On May 3, Emerson Electric Co. announced that net sales for the second quarter ended March 31, 2011, were $5.9 billion, an increase of 18% from the prior year quarter. Underlying sales increased 14%, acquisitions added 3%t and currency translation added 1%. Growth was strong across all global markets with underlying sales increasing 13% in the U.S., 17% in Europe, and 10% in Asia. Net earnings for the second quarter were $0.73 per share, increasing 38% compared with $0.53 last year.
Emerson Electric Co. is in the portfolios of Kenneth Fisher, Tom Gayner, Ruane Cunniff, John Keeley, Brian Rogers, James Barrow, David Dreman, Tweedy Browne, Arnold Van Den Berg, and Mario Gabelli.
Last week, Buy: Director Arthur F. Golden bought 2,000 shares of EMR stock. Buy: Exec. VP - Planning & Development Craig W. Ashmore bought 2,000 shares in May.
Celgene Corp. (CELG): CFO Jacqualyn A. Fouse Bought 2,000 Shares
CFO of Celgene Corp., Jacqualyn A. Fouse, bought 2,000 shares on June, 14, 2011, at an average price of $57.87. Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases. Celgene Corp. has a market cap of $26.78 billion; its shares were traded at around $57.87 with a P/E ratio of 22.1 and P/S ratio of 7.5.
Celgene Corp. is in the portfolios of Kenneth Fisher and Mario Gabelli.
On April 28, Celgene Corp. reported results for the first quarter of 2011. Non-GAAP total revenue increased 40% to $1.11 Billion; GAAP total revenue $1.13 billion. Non-GAAP net income increased 34% to $393 million; GAAP net Income $256 million.
Last week, Buy: CFO Jacqualyn A. Fouse bought 2,000 shares of CELG stock. Buy: Director Ernest Mario bought shares in March. Sell: Director Gilla Kaplan sold 20,000 shares this month.
Chesapeake Energy Corp. (CHK): Exec. Vice President & CFO Domenic J. Dell'osso Jr. Bought 4,000 Shares
Exec. Vice President & CFO of Chesapeake Energy Corp., Domenic J. Dell'osso Jr., bought 4,000 shares on June 10, 2011, at an average price of $28.02.
Chesapeake Energy Corp. is an independent oil and gas company engaged in the development, exploration, acquisition and production of onshore natural gas and oil reserves. Chesapeake Energy Corp. has a market cap of $18.43 billion; its shares were traded at around $28.02 with a P/E ratio of 9.6 and P/S ratio of 2. The dividend yield of Chesapeake Energy Corp. stocks is 1.1%. Chesapeake Energy Corp. had an annual average earnings growth of 9.8% over the past 10 years.
May 2, Chesapeake Energy Corporation announced its 2011 first quarter financial and operational results. For the quarter, Chesapeake reported a net loss to common stockholders of $205 million ($0.32 per fully diluted common share), operating cash flow of $1.404 billion, ebitda of $167 million on revenue of $1.612 billion and production of 280 billion cubic feet of natural gas equivalent.
Chesapeake Energy Corp. is in the portfolios of Richard Snow, T. Boone Pickens, George Soros, Ruane Cunniff, Ronald Muhlenkamp, David Dreman, Charles Brandes, Arnold Schneider, Carl Icahn, and Mario Gabelli.
This month, Buy: Chairman & CEO Aubrey K. Mcclendon and Buy: Exec. Vice President & CFO Domenic J. Dell'osso Jr. bought shares of CHK stock. Buy: Director V. Burns Hargis, Buy: Director Richard K. Davidson, and Buy: Director Merrill A. Jr Miller bought shares in March. Sell: EVP - Operations and COO Steven C. Dixon sold 30,000 shares this month and Sell: Director Charlest Maxwell sold 5,000 shares in March.
Eaton Corp. (ETN): SVP-Corp. Dev. & Treasury Kurt B. Mcmaken Bought 2,000 Shares SVP-Corp. Dev. & Treasury of Eaton Corp., Kurt B. Mcmaken, bought 2,000 shares on June 9, 2011, at an average price of $47. Eaton Corporation is a global diversified industrial manufacturer. Eaton Corp. has a market cap of $16.04 billion; its shares were traded at around $47 with a P/E ratio of 14.9 and P/S ratio of 1.2. The dividend yield of Eaton Corp. stocks is 2.9%. Eaton Corp. had an annual average earnings growth of 7.1% over the past 10 years.
On April 20, Eaton Corporation announced net income per share of $0.83 for the first quarter of 2011, an increase of 80% over the first quarter of 2010. Sales in the quarter were $3.8 billion, 23% above the same period in 2010. Net income was $287 million, up 85% over the first quarter of 2010. Net income in both periods included charges for integration of acquisitions. Before acquisition integration charges, operating earnings per share in the first quarter of 2011 was $0.84, an increase of 75% over the first quarter of 2010. Operating earnings for the first quarter of 2011 were $289 million, an increase of 80% over 2010.
Eaton Corp. is in the portfolios of George Soros, Kenneth Fisher, George Soros, David Williams, Richard Aster Jr, James Barrow, John Keeley, David Dreman, and Mario Gabelli.
Last week, Buy: SVP-Corp. Dev. & Treasury Kurt B. Mcmaken bought 2,000 shares of ETN stock. In March, Sell: Chairman and CEO Alexander M. Cutler sold shares. Sell: VC and CFO & Planning Officer Richard H. Fearon and Sell: VC & COO-Industrial Sector Arnold Craig sold shares in February.
Valeant Pharmaceuticals International Inc. (VRX): EVP, Interim CFO Philip Walden Loberg Jr. Bought 7,500 Shares
EVP, Interim CFO of Valeant Pharmaceuticals International Inc., Philip Walden Loberg Jr., bought 7,500 shares on June 9, 2011, at an average price of $50.53.
Valeant Pharmaceuticals International Inc. is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. Valeant Pharmaceuticals International Inc. has a market cap of $15.06 billion; its shares were traded at around $50.53 with a P/E ratio of 48 and P/S ratio of 12.8.
On May 9, Valeant Pharmaceuticals International Inc. announced first quarter financial results for 2011. Total revenue was $565.0 million in the first quarter of 2011 as compared to $219.6 million in the first quarter of 2010. The company reported net income of $6.5 million for the first quarter of 2011, or $0.02 per diluted share.
Valeant Pharmaceuticals International Inc. is in the portfolios of Glenn Greenberg, John Griffin, Ruane Cunniff, Jean-Marie Eveillard, Private Capital, Julian Robertson, Andreas Halvorsen, NWQ Managers Inc., and John Hussman.
Last week, Buy: EVP, Interim CFO Philip Walden Loberg Jr. bought 7,500 shares of VRX stock. Buy: EVP, GC & Corp. Sec. Robert Roswell Chai-onn and Buy: Director Norma Ann Provencio bought shares in May. Buy: Director Katharine Berghuis Stevenson and Buy: Director Norma Ann Provencio bought shares in March.
For the complete list of stocks that bought by their company executives, go to: Insider Buys.